Water Island Capital LLC Has $8.44 Million Position in NxStage Medical, Inc. (NXTM)

Water Island Capital LLC lessened its position in shares of NxStage Medical, Inc. (NASDAQ:NXTM) by 75.6% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 294,790 shares of the medical device company’s stock after selling 913,287 shares during the quarter. Water Island Capital LLC owned approximately 0.44% of NxStage Medical worth $8,437,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in NXTM. Kite Lake Capital Management UK LLP grew its position in shares of NxStage Medical by 228.3% in the third quarter. Kite Lake Capital Management UK LLP now owns 1,151,980 shares of the medical device company’s stock valued at $32,128,000 after purchasing an additional 801,048 shares during the period. JPMorgan Chase & Co. raised its stake in NxStage Medical by 56.3% during the third quarter. JPMorgan Chase & Co. now owns 1,187,250 shares of the medical device company’s stock worth $33,113,000 after purchasing an additional 427,745 shares during the period. Manikay Partners LLC purchased a new position in NxStage Medical during the third quarter worth about $11,853,000. Canada Pension Plan Investment Board purchased a new position in NxStage Medical during the third quarter worth about $7,792,000. Finally, Marshall Wace LLP raised its stake in NxStage Medical by 31.4% during the third quarter. Marshall Wace LLP now owns 1,148,542 shares of the medical device company’s stock worth $32,033,000 after purchasing an additional 274,664 shares during the period. Institutional investors own 81.28% of the company’s stock.

Shares of NxStage Medical stock traded up $0.04 on Tuesday, reaching $29.20. The company had a trading volume of 9,079 shares, compared to its average volume of 676,811. The company has a market capitalization of $1.94 billion, a price-to-earnings ratio of -132.68 and a beta of 0.25. NxStage Medical, Inc. has a 52-week low of $22.87 and a 52-week high of $29.33.

A number of equities research analysts have recently issued reports on the stock. Zacks Investment Research downgraded shares of NxStage Medical from a “buy” rating to a “hold” rating in a research note on Friday, February 1st. BidaskClub downgraded shares of NxStage Medical from a “buy” rating to a “hold” rating in a research note on Friday, December 28th.

COPYRIGHT VIOLATION NOTICE: “Water Island Capital LLC Has $8.44 Million Position in NxStage Medical, Inc. (NXTM)” was first reported by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this piece of content on another domain, it was stolen and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://sportsperspectives.com/2019/02/12/water-island-capital-llc-has-8-44-million-position-in-nxstage-medical-inc-nxtm.html.

About NxStage Medical

NxStage Medical, Inc, a medical technology company, develops, manufactures, and markets products and services for patients suffering from chronic or acute kidney failure. Its primary product includes the System One, a portable hemodialysis system, which is used primarily for home hemodialysis and a range of dialysis therapies to deliver in the home setting.

Featured Story: What does cost of debt say about a company’s financial health?

Institutional Ownership by Quarter for NxStage Medical (NASDAQ:NXTM)

Receive News & Ratings for NxStage Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply